Advertisement
Product › Details
CentoPharma software
Next higher product group | clinical research software | |
Status | 2018-11-16 sales start | |
Organisation | Centogene AG | |
Group | Centogene (Group) | |
Centogene AG. (11/16/18). "Press Release: Centogene Announces CentoPharma, World’s First Platform for Targeted Patient Cohort Identification". Rostock.
Provides intelligent access to a unique repository of genetic, biochemical and clinical information from global patient cohorts affected by rare hereditary diseases
CENTOGENE today announced the launch of CentoPharma 1.0, the world’s first CE labeled platform for targeted patient cohort identification. A tailored approach to targeting specific disease cohorts is crucial to research focused on improving the quality of life, integrated diagnosis, treatment and prevention of diseases.
The CentoPharma software gives intelligent access to CENTOGENE’s comprehensive data repository that combines phenotype, genotype and biochemistry information from a patient cohort analyzed at CENTOGENE through a fully compliant workflow, meeting the highest level of worldwide accredited quality. Dynamic search criteria enable the targeted compilation of individual customized cohorts based on desired geographical region, phenotype, genotype, and suspected or confirmed diagnosis. CentoPharma is powered by CentoMD®, the company’s unique repository of genetic, biochemical and clinical information from over 300,000 consented and curated individuals, including information for more than 3,500 diseases with 13,300 HPO (Human Phenotype Ontology) terms and over 117,000 individuals linked to HPO term(s).
“The increased number of designated orphan drugs and orphan drug development projects is a great step towards the accelerated support of patients suffering from a rare disease. In parallel, it demands unprecedented access to all available information within the shortest time. With CentoPharma, we are proud to provide access to a unique dataset of the global population, originating from more than 115 countries and associated with epidemiological data and clinical information – such as signs and symptoms of the disease. This will significantly contribute to speed up the drug development pipelines and the conduction of clinical trials by our pharmaceutical partners,” said Dr. Arndt Rolfs, founder and CEO of CENTOGENE.
About CENTOGENE
CENTOGENE unlocks the power of genetic insights to improve the quality of life of patients with rare genetic diseases. We achieve this through knowledge created by our worldwide diagnostic testing services incorporating global diversity, the world’s leading proprietary human genetic interpretation database- CentoMD® and by providing solutions for pharmaceutical companies developing life-changing therapies.
As one of the largest genetic testing companies worldwide, CENTOGENE is dedicated to translating the science of genetic information into solutions- bringing hope to patients with rare diseases and their families. www.centogene.com; www.centoMD.com
Contacts
CENTOGENE:
Doreen Niemann
+49 381 80113510
doreen.niemann@centogene.com
CENTOGENE Media Contact:
Lauren Arnold
MacDougall Biomedical Communications
+1 781-235-3060
larnold@macbiocom.com
Record changed: 2018-12-11 |
Advertisement
More documents for clinical research software
- [1] Sano Genetics Ltd.. (1/22/24). "Press Release: Sano Genetics Raises $11.4 Million Led by Plural to Power Precision Medicine Revolution with Seamless Trials". Cambridge....
- [2] AstraZeneca plc. (11/20/23). "Press Release: AstraZeneca Launches Evinova, a Health-tech Business to Accelerate Innovation across the Life Sciences Sector, the Delivery of Clinical Trials and Better Health Outcomes"....
- [3] uMotif Ltd.. (5/25/22). "Press Release: uMotif – the Patient-first Data Capture and Decentralized Clinical Trials Platform – Announces $25.5m of New Investment from a Fund Managed by Athyrium Capital Management". London & New York, NY....
- [4] CMS. (9/7/20). "Pressemitteilung: CMS begleitet Gründer des KI Start-ups Semalytix bei Serie-A Finanzierungsrunde". Berlin....
- [5] uMotif Ltd.. (9/3/20). "Press Release: uMotif Raises £5 Million to Power Decentralised Clinical Trials and Get Therapies to Patients Faster". London....
- [6] Semalytix GmbH. (8/31/20). "Press Release: Semalytix Closes Series A Investment Totaling €4.3m"....
- [7] Kaiku Health. (7/8/20). "Press Release: Kaiku Health Expands Collaboration with Roche in Digital Patient Monitoring and Management"....
- [8] Excelya SAS. (7/6/20). "Press Release: Excelya Welcomes Three European Contract Research Organizations to Become One Stop Provider Throughout Europe". Boulogne-Billancourt....
- [9] Boehringer Ingelheim. (2/18/20). "Press Release: Boehringer Ingelheim Launches Patient-Centric MyStudyWindow Powered by Carebox". Ingelheim & Raleigh, NC....
- [10] Novadiscovery SAS. (1/9/20). "Press Release: Novadiscovery Raises Series A Financing to Scale Its in silico Clinical Trial Platform – Debiopharm Leads the Round with EUR 5 Million"....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top